

Amendments to the Specification

Please add the priority information paragraph to the specification by inserting the following new paragraph before the first line of the specification:

This application claims the benefit of Great Britain Application No. 0221157.1, filed 12 September 2002.

An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b). Please insert the attached abstract, following the claims.

Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A method for the treatment and/or prophylaxis of pelvic pain, renal colic, biliary colic, functional dyspepsia, Barrett's metaplasia, dysphagia and pain associated therewith, in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of a vanilloid receptor antagonist.
2. (Original) A method according to claim 1, for the treatment and/or prophylaxis of renal colic or pain associated therewith.
3. (Original) A method according to claim 1, for the treatment and/or prophylaxis of biliary colic or pain associated therewith.
4. (Original) A method according to claim 1, for the treatment and/or prophylaxis of functional dyspepsia or pain associated therewith, such as, heartburn.
5. (Original) A method according to claim 1, for the treatment and/or prophylaxis of Barrett's metaplasia or pain associated therewith.

6. (Original) A method according to claim 1, for the treatment and/or prophylaxis of dysphagia or pain associated therewith.
7. (Original) A method according to claim 1, wherein the vanilloid receptor antagonist is an antagonist of the vanilloid receptor-1.
8. (Original) A method according to claim 7, wherein the vanilloid receptor-1 antagonist is *N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl)]urea.
9. (Original) A pharmaceutical composition for the treatment and/or prophylaxis of pelvic pain, renal colic, biliary colic, functional dyspepsia, Barrett's metaplasia, dysphagia and pain associated therewith, which composition comprises a vanilloid antagonist, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier therefor.
10. (Cancelled)
11. (Cancelled)

REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/EP2003/010261 into the U.S. National Phase of prosecution. In the specification, a new paragraph has been added to the first line of the specification to include the priority information. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b). Claims 10 and 11 have been cancelled. Entry of this amendment into the record is requested.

Respectfully submitted,



Soma G. Simon

Attorney for Applicants

Registration No. 37,444

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5019
Facsimile (610) 270-5090